Zoltan Derdak
Medical Director Takeda Pharmaceutical
Seminars
Thursday 3rd December 2026
Distinguishing Hot Versus Cold Fibrosis: Developing Rapid Progressor Signatures to Predict Treatment Response & Optimize Trial Design
11:00 am
- Defining hot & cold fibrosis endotypes using histological features, immune cell infiltration, & molecular signatures
- Developing non-invasive biomarker panels to identify patients in inflammatory versus quiescent fibrotic phases without requiring biopsy
- Tailoring therapeutic approaches & trial inclusion criteria based on disease endotype to maximize treatment effect size
